Intrinsiqq

Spago Nanomedical AB (SPAGO.XSTO) Financials

All currency values in kr millions unless otherwise noted

Scroll

Income Statement
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenuekr 0kr 2kr 1kr 1kr 1
Cost of Revenuekr 11kr 14kr 24kr 17kr 17
Gross Profit-kr 11-kr 12-kr 23-kr 16-kr 17
Total Operating Expenseskr 15kr 21kr 20kr 23kr 22
Operating Income-kr 26-kr 34-kr 43-kr 39-kr 39
Non-Operating
Net Interest Expensekr 0————
Net Income
Net Income-kr 27-kr 33-kr 42-kr 39-kr 39
Per Share Data
Revenue Per Sharekr 0.00kr 0.01kr 0.01kr 0.02kr 0.02
EPS (Basic)-kr 0.07-kr 0.11-kr 0.43-kr 0.58-kr 0.95
EPS (Diluted)-kr 0.07-kr 0.11-kr 0.43-kr 0.58-kr 0.95
Shares Outstanding380.3M295.5M98.2M67.3M41.3M

Spago Nanomedical AB (SPAGO.XSTO) financials: revenue, profit and margins

Spago Nanomedical AB (SPAGO.XSTO) generated about SEK 437,000.00 in revenue and -SEK 27 million in net income (a -6,076.4% net margin) over the trailing twelve months, growing at roughly -9.8% a year. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Spago Nanomedical AB's (SPAGO.XSTO) revenue?+

Spago Nanomedical AB generated about SEK 437,000.00 in revenue over the trailing twelve months. Revenue has grown at roughly -9.8% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Spago Nanomedical AB profitable?+

Spago Nanomedical AB reported about -SEK 27 million in net loss over the trailing twelve months, a net margin of roughly -6,076.4%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Spago Nanomedical AB's profit margins?+

Spago Nanomedical AB runs a gross margin of about -2,527.2%, an operating margin of about -6,059.3%, a net margin of about -6,076.4%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Spago Nanomedical AB growing?+

Spago Nanomedical AB's revenue has compounded at roughly -9.8% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside SPAGO.XSTO's margins and free cash flow. This is analysis from company filings, not investment advice.

How the market compares: How many US companies are profitable

Related stocks: Biotechnology

Spot a number that looks wrong?

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.